Clinical Trials Logo

Relapsed Pediatric ALL clinical trials

View clinical trials related to Relapsed Pediatric ALL.

Filter by:
  • None
  • Page 1

NCT ID: NCT05334823 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

Start date: January 26, 2022
Phase: Phase 2
Study type: Interventional

This is a phase II clinical study to evaluate the safety and efficacy of pCAR-19 B cell autologous infusion preparation in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

NCT ID: NCT04888468 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

Start date: November 5, 2019
Phase: Phase 1
Study type: Interventional

This is a phase I clinical study to evaluate the safety and tolerability of pCAR-19B in patients with relapsed or refractory B-ALL, and to obtain the maximum tolerated dose of pCAR-19B and phase II Recommended dose.

NCT ID: NCT04562792 Completed - Clinical trials for Refractory Acute Myeloid Leukemia

Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia

Start date: May 8, 2020
Phase: Phase 2
Study type: Interventional

In this pilot study, eligible pediatric patients will be treated with 5 consecutive days of low dose daunorubicin. All patients who receive low dose daunorubicin will be evaluated daily for potential toxicity during those 5 days. Once the patient has received 5 doses of daunorubicin, subsequent therapy will be at the discretion of the primary oncology team.

NCT ID: NCT04033627 Recruiting - Clinical trials for Relapsed Pediatric ALL

TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia

Start date: November 10, 2020
Phase: N/A
Study type: Interventional

This is a multi-center clinical study in China using CliniMACS TCRα/β+ and CD45RA+ T cell depleted stem cell grafts from haploidentical donors for hematopoietic stem cell transplantation in children.

NCT ID: NCT03938987 Recruiting - Clinical trials for Relapsed Non Hodgkin Lymphoma

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

ACIT001/EXC002
Start date: March 3, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Autologous, unselected CD3+ lymphocytes collected from apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ).

NCT ID: NCT00439296 Terminated - Clinical trials for Acute Lymphoblastic Leukemia

ABT-751 With Chemotherapy for Relapsed Pediatric ALL

Start date: May 22, 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). The phase I portion of this study is being done to find the highest dose of ABT-751 that can be given safely in combination with other chemotherapy drugs. A safe dose is one that does not result in unacceptable side effects. After a safe dose for ABT-751 given with chemotherapy has been found, the study will add additional patients to find out if ABT-751 (given at the maximal safe dose) when given with additional chemotherapy is an effective therapy for the treatment of children with relapsed ALL. It is expected that approximately 15-35 children and young adults will take part in this study.